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Abstract  
 
Tacrolimus (FK506) and cyclosporin A (CsA) are immunosuppressants commonly used in 
transplantology. Their neuroprotective actions have also frequently been reported. Unfor-
tunately, after prolonged administration, the drugs have numerous negative neurological 
side-effects which could also be observed in paediatric clinical cases. Since the problem 
has never been explored experimentally, the present study focuses on FK506 and CsA influ-
ence on the developing rat brain. Six- and 30-day-old rats (P6s and P30s, respectively) re-
ceived two injections of FK506 or CsA, at a 24-hr interval. Control rats were injected with 
vehicle alone (Cremophor and ethanol mixture). When the rats were 60-day-old, weights 
and sizes of their brains were recorded. Additionally, quantitative assessment of calretinin- 
(CR+) and parvalbumin-immunopositive (PV+) inhibitory neurons was performed. In com-
parison to naive or vehicle-injected controls, FK506 or CsA-treated P6s showed decreases 
in the brain weight. In P30s, a decrease in the brain weight was observed only following 
the vehicle injections. In P6s, CsA injections reduced both CR+ and PV+ neuronal popula-
tions while FK506 injections reduced only numbers of PV+ neurons. In P30s, injections of the 
vehicle alone, but not those of FK506 or CsA, led to significant reductions of the CR+ and 
PV+ neurons. Generally, the results suggest negative long-term effects of FK506 or CsA on 
the developing brain. Interestingly, the negative effects of the vehicle were much stronger. 
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Introduction 
 
Every year the number of successful organ 
transplantations increases. However, final re-
sults of the surgical interventions are deter-
mined by effectiveness of long-term immuno-
suppressive therapy. Among immunossuppre-
sive drugs, Tacrolimus (FK506) and cyclosporin 
A (CsA) are the most frequently used but, un-
fortunately, negative side-effects of their pro-
longed application are often observed. They 
include headaches, altered mental function-
ing, tremours, cerebellar syndromes, reversible 
leukoencephalopathy, increased risks of tu-
mour growth1,2 or even seizures3.  On the other 
hand, in experimental studies these drugs 
showed strong neuroprotective actions follow-
ing cerebral ischemia4,5,6,7, spinal cord ische-
mia8 or traumatic brain injury9. So far, those 
experiments were carried out on adult animals 
or in vitro. To the best of our knowledge, no 
published systematic research report describes 
effects of CsA or FK506 on the developing cen-
tral nervous system. Since the drugs are com-
monly administered to children and adoles-
cents in clinical immunosuppressive therapy, 
exploration of their effects on the developing 
brain appears important. 
 
In order to explore the above presented prob-
lem, we exposed the rat brain to FK506 or CsA 
on postnatal days 6 or 30, and investigated 
what would be the effect of this intervention 
on the adult, 60-day-old brain. The two age 
groups represent considerably different stages 
of the brain development. The first one is char-
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acterised by dynamic glial cell production, 
neuronal apoptosis10 being of importance to 
functional abilities of the brain in adulthood. At 
the second stage, the two developmentally 
programmed processes are basically stopped 
and different cell populations within the brain 
approach their final quantities. We focused our 
attention on populations of GABA-ergic in-
terneurons containing calcium-binding proteins 
(CaBPs) – parvalbumin or calretinin. Because of 
their ability to bind calcium, these proteins are 
involved in many developmental processes 
(cell differentiation, elongation of nervous cell 
processes, cell motility)11. On the other hand, 
the same ability allows these proteins to reduce 
calcium overloads, which could initiate neu-
rodegenerative changes or modify neuronal 
conductance. Since any developmental pa-
thology of the neuronal population may have 
severe consequences to the brain function in 
adulthood, including epileptic disorders, the 
obtained results may be of importance to the 
strategy of prolonged immunosuppressive 
treatments in children and adolescent patients. 
 
Methods 
 
Animals 
 
All animal-use procedures followed ‘Principles 
of Laboratory animal care’, NIH publication 
(Vol 25, No. 28 revised 1996) and were also ap-
proved by the Bioethical Commission of the 
Jagiellonian University. 
 
Adult Wistar rats were obtained from an animal 
colony of the Institute of Paediatrics, Collegium 
Medicum, Jagiellonian University, Kraków and 
maintained under conditions of controlled tem-
perature (20 ±2oC) and illumination (12h light/
dark cycle). A solid diet (Labofeed) and water 
were available ad libitum. 
 
Pregnant females were housed in individual 
cages and allowed to give birth. Within 24 hrs. 
postpartum, the litters were reduced to 10. The 
young rats were weaned at 28 days of age.  
 
FK506 or Cyclosporin A administration 
 
Male 6-day- or 30-day-old rats (P6s and P30s, 
respectively) obtained from the females were 
injected i.p. with 2 mg/kg of FK506 (Prograf, 
Fujisawa; n=12 and n=8, respectively for each 
age group) or with 20 mg/kg of cyclosporin A 
(Novartis; n=12 and n=7, respectively) T. The 
injection was repeated 24 hours later. Each 
pharmaceutical was dissolved in saline con-
taining 0.25% polyoxyl hydrogenated castor oil 
(BASF, Germany) and 0.25% ethanol. Control 
rats were injected with the vehicle alone (n=11 
and n=9, respectively). For comparative pur-
poses, naive rats (n=13) were also used. Neuro-
protective efficacy of the above-indicated 
dosage of FK506 and CsA used in the present 
study has been tested by Uchino et al.12 and 
Sullivan et al.13. 
 
Tissue fixation and staining procedures 
On day 60 of postnatal development, each rat 
received a lethal dose of pentobarbital and 
was perfused transcardially with 0.9% NaCl fol-
lowed by 4% paraformaldehyde in 0.1M phos-
phate buffer, pH 7.4. After removing from the 
skull, the medulla was dissected, the brain was 
weighted, post-fixed overnight and embed-
ded in paraffin. Ten mm-thick frontal sections 
were cut and mounted on slides covered with 
polylysine (Sigma). 
 
Immunohistochemical procedure  
 
The brain sections on slides were deparafinised, 
hydrated, rinsed in Tris buffer (TB) (5 min) on a 
shaker table and treated with 10% H2O2 in TB 
for 30 min. This was followed by another wash 
in TB (3 x 5 min) and by digestion in a 0.1% tryp-
sin solution in TB, pH 7.8 for 1 h. Subsequently, 
the slides were washed in TB (3 x 5 min) and 
incubated for 48 hrs at 4oC with primary anti-
bodies: monoclonal anti-parvalbumin 
(Chemicon, MAB1572) or rabbit anti-calretinin 
(Chemicon, AB5054) dissolved in 0.5% Triton X-
100-containing TB, each at concentration 
1:1000. Thereafter, the slides were washed in TB 
(3 x 10 min) and incubated with secondary 
antibodies: goat anti-mouse or goat anti-rabbit 
(Sigma), respectively (1:100 in TB, 1 hr at room 
temp.). Following a further wash in TB (3 x 10 
min), the sequence was completed by the 
addition of the mouse or rabbit PAP (Sigma), 
respectively (1:200 in TB, 1 hr at room temp.). 
The slides were then rinsed with TB (3 x 10 min), 
and the sites of HRP binding were visualised 
using diaminobenzidine (Sigma) and H2O2 as 
the substrate (5 mg diaminobenzidine in 10 ml 
of TB containing 5 ml of 30% H2O2, 15 min). Fi-
nally, the slides were counterstained with cresyl 
violet, dehydrated and coverslipped using De-
PeX (Fluka). Controls of the immunostaining, 
performed by omitting the primary or primary 
plus secondary antibody, gave negative re-
sults.  
 
Nerve cell counting  
   
Two sections from each brain at the level of 
the anterior commissure were chosen for mi-
croscopic examination using a square frame-
containing eyepiece. At a magnification of 
1000X, the frame delimited a 100 X 100 mm 
area. In each section, standard sample zones 
within dorsal parts of each cerebral hemi-
sphere were delineated (Fig. 1). The zones 
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were examined square by square and all par-
valbumin (PV+) or calretinin-immunopositive 
(CR+) neurons (Fig. 2) were recorded. Surface 
areas of the examined zones were also meas-
ured using a 2.5x objective on a Nikon Micro-
phot SA microscope mounted with a JVS col-
our camera connected to an image analysis 
computer system. Finally, numbers of im-
munopositive cells per mm2 of the examined 
zone were calculated.  
Figure 1. Delineation of microscopically examined standard 
zones. S, axis of symmetry of the brain section at the level of 
the anterior commissure (AC); a, line perpendicular to the 
axis S passing through the top of lateral ventricle. Shadowed 
areas - zones within the dorsal part of the cerebral hemi-
spheres where calretinin or parvalbumin-immunopositive 
neurons were counted, St, stripes of tissue where Nissl-stained 
neurons were counted. 
 
To detect possible quantitative changes of the 
whole neuronal population, an additional 
counting of Nissl-stained neurons was carried 
out. For comparative purposes, the counting 
method had to be similar to the above de-
scribed non-stereological quantitative assess-
ment applied to PV+ or CR+ neurons. Conse-
quently, the density of Nissl-stained cells was 
calculated and expressed as the average 
number of neurons per one mm2 of the tissue 
section area. From technical reasons, the time-
consuming counting was limited to stripes of 
tissue between the lateral ventricle and the 
surface in each cerebral hemisphere shown 
(Fig. 1). The width of the stripe was 200 mm i.e. 
it included two sides of the frame used during 
the counting. All visible neurons with a clearly 
defined nucleus and cytoplasm, within the ex-
clusion lines of the frame, were counted under 
oil immersion using a 100x objective. Micro-
scopic observations were carried out without 
the knowledge of the previous treatment of 
the rats. 
 
 
 
 
 
 
 
Figure 2. Neurons immunoreactive for calretinin (A) and 
parvalbumin (B) in the cerebral cortex. Scale bar shows 100 
mm. 
Zuzanna Setkowicz, Jaroslaw Kadulski 
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Statistical analysis 
 
Statistical analysis was performed with the STA-
TISTICA work package for Windows (Statsoft, 
Inc.). Because of non-normal distribution of 
data, we used the Kruskall-Wallis analysis of 
variance (differences among all the examined 
groups) followed by Mann-Whitney U test 
(differences between groups). The level of sta-
tistical significance was set at 0.05. 
 
Results 
 
All the measurements were carried out on the 
histological material from brains of 60-day-old 
rats which were injected with CsA, FK506 or 
vehicle on P6 or P30, i.e. 54 or 30 days earlier. 
We evaluated statistically relations between 
the following groups: (1) naive (non-treated 
rats) or injected with (2) vehicle alone, (3) 
FK506 or (4) CsA at each of the two develop-
mental stages.  
 
Brain weight  
 
In animals treated with vehicle alone on P6, the 
brain weight remained unchanged on P60 in 
comparison to the group of naive, non-treated 
rats (Fig. 3 A). However, injections of FK506 dis-
solved in the vehicle made the brain weight 
significantly lower than that in non-treated 
controls (P<0.0002) and also than in those 
treated with the vehicle alone (P<0.0001) or 
CsA (P<0.008). Following CsA injection on P6, 
the brain weight was lower that in vehicle-
treated rats (P<0.02) but not when compared 
to naive rats.  
 
In the group of 30-day-old rats, only the vehicle 
injections led to a decrease in the brain weight 
on P60 (P<0.04 vs. naive rats, Fig. 3 B) but no 
effect of FK506 or CsA was observed. It is note-
worthy that neither the average body weight 
nor the brain-to-body weight ratio were af-
fected in any of the differently treated animal 
groups. 
 
Changes in neuronal populations 
 
Quantitative assessment of Nissl-stained or CR+ 
and PV+ neurons detected no significant differ-
ence between two hemispheres in any of the 
examined groups. Therefore, further statistical 
analysis of differences between experimental 
and control groups was performed on the basis 
of average data calculated for both cerebral 
hemispheres. 
 
None of differently treated groups of 6- or 30-day-
old animals showed any significant change in the 
density of Nissl-stained neurons calculated per 
one mm2 of the examined area. 
Figure 3. Changes in the brain weight. Rats injected on post-
natal days 6 (A) or 30 (B) were examined on P60. Abbrevia-
tions for Figs. 3-5: N – naive, control rats; Veh, FK506, CsA – 
rats treated with vehicle alone or with FK506 or CsA, respec-
tively. Numbers of animals belonging to each group are 
shown in square brackets. The box and whisker diagram 
shows the median (small black rectangle in the box), the 25–
75% variability range (large box), and maximal and minimal 
values (whiskers). NS means that the difference was non-
significant. Decimal indexes located over a box show statisti-
cal significance of difference between a differently-treated 
group and the group of control rats. Indexes located at 
double-headed arrows show statistical significance of differ-
ences between two examined groups (Mann-Whitney U 
test). The decimal index in the upper right corner of the dia-
gram shows statistical significance of differences between 
the examined groups (Kruskall-Wallis test). 
 
a. Calretinin-immunopositive (CR+) neuronal 
population 
 
In P6s, both vehicle and CsA injections signifi-
cantly decreased number of CR+ neurons 
(P<0.01 and P<0.004 respectively, Fig. 4 A) in 
comparison to the control, naive group. The 
FK506-injected group showed no significant 
change. 
 
In P30s, injections of the vehicle alone de-
creased the number of CR+ neurons (Fig. 4 B) 
in comparison to naive controls (P<0.006). 
FK506 and CsA injections had no statistically 
significant effect. 
 
b. Parvalbumin-immunopositive (PV+) neuronal 
population  
 
Treatments of P6s with the vehicle alone, FK506 
or CsA significantly decreased numbers of PV+ 
cells (P<0.0004, P<0.02, P<0.0007, respectively, 
in relation to naive rats, Fig. 5 A). Following the 
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same treatments performed in P30s, only injec-
tions with the vehicle alone resulted in reduc-
tion of the PV+ neuron quantity (P<0.007 vs. 
naive controls, Fig. 5 B).   
Figure 4. Changes in the number of calretinin-
immunopositive neurons per 1 mm2 of the brain section area 
within the dorsal part of the cerebral hemisphere at the level 
of the anterior commissure shown in Fig. 1. For further expla-
nations see Fig. 3. 
Figure 5. Changes in the number of parvalbumin-
immunopositive neurons per 1 mm2 of the brain section area 
within the dorsal part of the cerebral hemisphere at the level 
of the anterior commissure shown in Fig. 1. For further expla-
nations see Fig. 3.  
 
Discussion 
 
The aim the present study was to answer the 
question if immunosuppressive agents FK506 
and CsA could affect the developing brain. 
Until now, no systematic study has shown an 
evidence of permanent developmental 
changes in the brain evoked by the treatment 
with FK506 or CsA. The situation appears some-
what surprising since both substances have 
been routinely used for many years in post-
transplantational therapy in children. In such 
clinical trials, several neurological side-effects 
have been observed1, 2, 14,15. The problem be-
comes more important in several years long 
therapy after the organ transplantation in pedi-
atric patients who require significantly higher 
doses of the drugs because of significantly higher 
metabolic rate and rapid clearance16, 17. Thus, on 
the basis of clinical experience, in the present 
experiment negative influences of the two 
drugs on the developing brain could rater be 
expected. On the other hand, high neuropro-
tective efficiency of the used dosage has al-
ready been recognised in many previous ex-
periments which, however, have also been 
performed only on injured adult brains12, 13. 
 
In the present study, both FK506 and CsA were 
used in formulas supplied by their manufactur-
ers for clinical purposes, i.e. dissolved in the 
mixture of Cremophor and ethanol. Several 
cases of negative influences of FK506 and CsA 
on the developing brain were observed such 
as a decrease of its weight or reduction of CR+ 
or PV+ neuronal populations. It is noteworthy, 
however, to mention that, from the theoretical 
point of view, a possibility of positive effects in 
the same respects could also be considered. 
Both negative and positive changes would 
point to structural modifications of unrecog-
nized consequences, including functional im-
pairment of the brain. In the present study, 
however, only negative changes were re-
vealed or their total absence. 
 
The obtained results can somewhat surprisingly 
be concluded that highly significant reduction 
in the quantity of CR+ and PV+ neuronal popu-
lations could be evoked by the vehicle alone, 
i.e. by the mixture in which FK506 or CsA were 
dissolved and what was previously reported as 
biologically inactive7. Moreover, the vehicle 
alone, when administered on postnatal day 30 
but not on day 6, significantly reduced the 
brain weight in 60-day-old rats. This fact ap-
pears to be preliminary evidence of severe 
generalised changes which need more de-
tailed investigations since the present study 
show only a very small, selected aspect of the 
whole phenomenon. 
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In the present experimental situation an appar-
ently paradoxical problem arose: if and at 
what degree the presence of FK506 or CsA 
minimised or amplified negative effects of the 
vehicle itself. It has, however, been proven that 
FK506 dissolved in the vehicle and adminis-
tered to six-day-old rats abrogated negative 
effect of the vehicle administered alone 
(difference of high statistical significance). A 
similar effect did not take place when CsA was 
dissolved in the vehicle. In the same age 
group, reduction of PV+ neurons following in-
jections of FK506 or CsA in the vehicle was simi-
lar to that evoked by the vehicle alone. 
 
The presence of FK506 or CsA in the vehicle 
before injections in 30-day-old rats abrogated 
strong negative effects on the quantity of CR+ 
and PV+neurons detected following injections 
of the vehicle alone.  
 
Thus, the results clearly prooved that the vehi-
cle itself became the cause of strongest nega-
tive long-term effects. There are many pub-
lished reports on neurotoxic properties of its 
component - Cremophor. Windenbank et al. 
[18] observed that in vitro Cremopor inhibited 
the neurite growth of DRG neurons and de-
creased activity of C proteinase regulating 
phosphorylation of many proteins engaged in 
cell proliferation and differentiation19. Since 
Cremophor can disturb mitochondrial respira-
tory processes20, the decrease in the quantity 
of CR+ and PV+ neurons observed in our study 
might be the result of its toxic ability especially 
when mixed with ethanol. In fact, during early 
developmental periods ethanol induces neu-
ronal degeneration21. In the rat, during the first 
postnatal week, CaBPs-containing neurons 
undergo considerable developmental 
changes22. However, according to the report 
by Granato23 exposure of neonatal rats during 
this period can even increase the population 
of CR+ without any effect on the quantity of 
PV+ neurons. Neverrtheless, the overall popula-
tion of CaBPs-immunopositive neurons re-
mained stable.  
 
We were aware that the toxic action of the 
vehicle itself could result not only in quantita-
tive reduction of CR+ and PV+ neuronal popu-
lations but also in lower contents of calretinin 
and/or parvalbumin in affected neurons. The 
latter, being also of importance to functional 
features of the brain, could lead to decreases 
in numbers of neurons detected immunocyto-
chemically in the present study. 
 
Calcium binding proteins (CaBPs): parvalbumin 
and calretinin are present in GABA-ergic neu-
rons24, where they are involved in the regula-
tion of Ca++ level determining their normal 
functional abilities. Cellular Ca ++ overload 
can frequently initiate neurodegenerative 
changes leading to cell death25. The main role 
of CaBPs consists in binding of Ca++ , which is 
engaged in the cell division processes, axon 
elongation and cell motility11. 
 
The treatment with CsA or FK506  could selec-
tively reduce the CaBPs-containng neuronal 
population without any effect on the total quan-
tity of neurons as it was observed in our experi-
ment. Finally, that might result in changes in sus-
ceptibility to seizures in animals which after injury 
were injected with neuroprotectants26, 27. 
 
The present report demonstrates that a rela-
tively small dose of FK506 or CsA can interrupt 
the development of inhibitory CaBPs-
containing interneurons. Moreover, the pre-
sented facts point to adverse effects of the 
commonly used vehicle on the developing 
nervous system. It cannot be excluded that the 
vehicle determines, at least in part, negative 
side-effects of the neuroprotectants frequently 
observed in clinical practice.  
 
It appears, therefore, that further experimental 
and clinical verification of the results presented 
here could to be of importance for planning 
an optimal post-transplantation therapy in 
paediatric patients. 
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